Theragen Bio

What Theragen Bio does

Theragen Bio is a South Korea-based genomic services and AI-driven biopharmaceutical company providing next-generation sequencing (NGS)-based genomic analysis, bioinformatics services, and personalized cancer therapeutics development. The company operates as a subsidiary of Theragen Etex with 51-100 employees, headquartered in Suwon, Gyeonggi-do, and serves healthcare and medical institutions, pharmaceutical and biotech companies, academic researchers, and consumer health segments. In 2025, the company reported revenue of 10.5 billion KRW (~$7.5M USD) and achieved its first net profit of 920 million KRW with a 23.8% improvement in operating loss. The company holds ISO 27001 and ISO 27701 certifications maintained for four consecutive years and is currently expanding internationally, with sales beginning in Japan in Q1 2025.

The company's core technology is the proprietary DEEPOMICS AI platform, comprising three deep learning modules: DEEPOMICS NEO (personalized neoantigen prediction incorporating both MHC-peptide binding and T-cell activation), DEEPOMICS MARKER (automated disease subtype classification from transcriptome data), and DEEPOMICS FFPE (deep neural network-based removal of artifacts from formalin-fixed paraffin-embedded tissue samples). DEEPOMICS NEO is protected by three registered patents covering HLA Class I prediction, HLA Class II prediction, and rare HLA resolution specifically tuned for East Asian populations, while the FFPE methodology was peer-reviewed and published in Scientific Reports in February 2024. Supporting infrastructure includes a high-throughput Illumina NovaSeq 6000 S4 platform (1,000th run milestone achieved December 2023) and the first Element Biosciences AVITI system installed in South Korea. The company has strategic integrations with Agilent (NGS pipeline co-development, 2023), Arontier (joint AI cancer vaccine platform development, 2024), Korea University Ansan Hospital (clinical research MOU, 2023), and participates in Korea's PAVE (ARPA-H equivalent) personalized cancer vaccine initiative.

Theragen Bio monetizes through multiple revenue streams: NGS sequencing services (including proprietary TCR Seq), bioinformatics and clinical sequencing analysis, Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser), and direct-to-consumer healthcare offerings (TherAbiome microbiome analysis, Hellojin disease prediction, Genestyle DTC genetic testing) distributed through the Theragen Health subsidiary and partner channels including Genestyle Mall. A drug discovery platform developing personalized cancer vaccines using NGS, mRNA, and LNP technologies is in development, with the first-in-class "dark matter" therapeutic R&D effort backed by partnerships with Arontier and participation in the Korean PAVE project. The company has also been selected as priority negotiating partner for genome production institution in the National Integrated Bio Big Data Construction Project (October 2024), positioning it as a foundational player in Korea's national genomic data infrastructure.

Name

Theragen Bio

Legal name

(주)테라젠바이오

Website

https://theragenbio.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Theragen Bio is a South Korean genomic services and AI-driven biopharmaceutical company providing NGS sequencing, bioinformatics analysis, Bio IT solutions, and personalized cancer vaccine development through its proprietary DEEPOMICS platform, serving pharmaceutical, healthcare, and research organizations in Korea and Japan.

Ownership category

akta.pro rank

Product category

Genomics & Bioinformatics Services

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Genomic sequencing services
• Bioinformatics analysis
• Clinical NGS sequencing
• AI neoantigen prediction
• Microbiome analysis services

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. NGS Services: Next Generation Sequencing services including TCR Seq (T-cell receptor sequencing) services that have been localized using proprietary technology
2. Bioinformatics Services: Bioinformatics analysis services using proprietary DEEPOMICS platform
3. Clinical Sequencing: Clinical sequencing services for diagnostic purposes
4. Bio IT Solutions: LIMS solutions for NGS and healthcare including NGS LIMS and Healthcare LIMS
5. Healthcare Services: Direct-to-consumer and clinical microbiome analysis services (TherAbiome, Hellojin, GenStyle)
6. Drug Discovery Platform: First-in-class dark matter therapeutic R&D including personalized cancer vaccines using NGS, mRNA, and LNP technologies

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Theragen Bio is a global genomic service provider and AI-based biopharmaceutical company offering NGS sequencing services, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser) to enterprise clients in healthcare and pharma. Its core differentiator is the proprietary DEEPOMICS® AI platform with modules for neoantigen prediction, disease subtyping, and FFPE artifact removal, underpinning personalized cancer vaccine R&D and precision medicine workflows. Direct-to-consumer microbiome analysis (TherAbiome) and genetic risk prediction (Hellojin, Genestyle) services are offered alongside, primarily through its Theragen Health subsidiary.

Product overview

Theragen Bio is a global genome analysis service and platform-based new drug development company offering an integrated portfolio of NGS-based genomic services and AI-powered bioinformatics solutions. The core offering centers on the DEEPOMICS AI platform with three modules: DEEPOMICS NEO (AI-based neoantigen prediction for personalized cancer vaccines), DEEPOMICS MARKER (disease subtype classification and biomarker discovery), and DEEPOMICS FFPE (deep learning-based variant calling for FFPE samples). Supporting services include NGS sequencing, bioinformatics analysis, clinical sequencing, and Bio IT solutions (NGS LIMS, Healthcare LIMS, Genome Browser). Healthcare offerings comprise THERAbiome (microbiome analysis), 헬로진 (cancer/disease prediction), and 진스타일 (DTC healthcare). The company serves pharmaceutical companies, healthcare institutions, and research organizations with genomic data services and precision medicine solutions.

Differentiator

Problem solved

Functional benefit

Brands

• TherAbiome (테라바이옴): Microbiome analysis service that analyzes gut microbiome using Next Generation Sequencing technology to provide personalized health monitoring including gut health, metabolism, cardiovascular health, and lifestyle tips.
• Genestyle (진스타일)
• Hellojin (헬로진)
• DEEPOMICS®
• DEEPOMICS® NEO
• DEEPOMICS® MARKER
• DEEPOMICS® FFPE

Products and services

• NGS Services Next-generation sequencing services providing comprehensive genomic profiling, data generation, and analysis for healthcare institutions, pharmaceutical companies, and research organizations.
• Bioinformatics Services Bioinformatics data analysis services leveraging proprietary DEEPOMICS® AI platform and deep learning capabilities to interpret complex genomic data for research and clinical applications.
• Clinical Sequencing Clinical-grade sequencing services for diagnostic and precision medicine applications, providing clinical decision support for healthcare providers.
• NGS LIMS Laboratory Information Management System (LIMS) designed for NGS workflows and genomic data management, providing sample tracking, workflow management, and data integrity controls for genomics laboratories.
• Healthcare LIMS Healthcare-focused laboratory information management system for clinical and diagnostic operations, supporting sample management, reporting, and compliance for healthcare institutions.
• Genome Browser Genomic data visualization and browsing tool for analyzing and interpreting genomic information, supporting researchers and clinicians in exploring sequencing results.
• TherAbiome (테라바이옴) Microbiome analysis service using NGS technology to analyze gut microorganisms and provide personalized health monitoring and therapy recommendations, including gut health, metabolism, cardiovascular health, and lifestyle insights.
• Hellojin (헬로진) Direct-to-consumer cancer and disease prediction service providing personalized health risk assessments through genomic analysis for early disease risk awareness.
• Genestyle (진스타일) Direct-to-consumer (DTC) healthcare service offering personal genetic testing and health risk assessment services, distributed through the Theragen Health subsidiary and Genestyle Mall partner channel.
• DEEPOMICS NEO AI-based personalized neoantigen prediction platform that identifies somatic mutations in patient tumor tissue and predicts patient-specific neoantigens tailored to individual MHC profiles using deep learning models that consider both MHC-neoantigen binding and T-cell activation. Offered as a co-development platform for cancer vaccine R&D with pharmaceutical partners.
• DEEPOMICS MARKER Deep learning-based platform that automatically discovers and classifies disease molecular subtypes and identifies specific biomarkers and signatures for each subtype from transcriptome data without requiring normal controls. Supports patient stratification and therapeutic target identification for pharmaceutical research.
• DEEPOMICS FFPE Deep neural network-based AI model that removes FFPE-derived artifacts while preserving true somatic mutations, enabling accurate variant calling from challenging formalin-fixed paraffin-embedded tissue samples commonly used in cancer research and clinical archives.
• T-cell Receptor Sequencing (TCR Seq) Proprietary T-cell receptor sequencing service using localized proprietary technology capable of analyzing difficult FFPE samples with high efficiency for immuno-oncology research and cancer vaccine development.

Quantifiable outcome

• DEEPOMICS® NEO demonstrated superior anti-tumor efficacy in B16F10 melanoma tumor model compared to conventional methods in preclinical studies
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Korean National Integrated Bio Big Data Construction ProjectcoreStrategic or Co-development Partner · 29 October 2024Selected as priority negotiating partner (유전체 생산기관 우선협상대상자) for the National Integrated Bio Big Data Construction Project genome production institution, indicating government-level partnership for national genomic data infrastructure.
• ArontiercoreStrategic or Co-development Partner · 17 January 2024Joint development contract for AI-based personalized cancer vaccine design platform using DEEPOMICS® NEO technology. Collaboration aimed at developing personalized cancer vaccine design capabilities.
• IlluminacoreTechnology or Integration · 8 December 2023Achieved Illumina NovaSeq 6000 S4 1000th run milestone, demonstrating high-volume sequencing capabilities and strong partnership with Illumina for next-generation sequencing services.
• Korea Bio Master High School (한국바이오마스터고)minorOthers · 7 December 2023Donated genetic analysis equipment to Korea Bio Master High School for educational purposes, demonstrating corporate social responsibility.
• AgilentcoreTechnology or Integration · 25 September 2023NGS analysis pipeline development MOU for genomic profiling collaboration with Agilent (NASDAQ: A), enhancing genomic profiling capabilities through joint development of NGS analysis pipelines.
• Korea University Ansan Hospital (고대안산병원)coreStrategic or Co-development Partner · 10 July 2023MOU for precise genome information production and analysis collaboration with Korea University Ansan Hospital, strengthening clinical research capabilities.
• PAVE (Korean ARPA-H)coreStrategic or Co-development PartnerParticipation in the Korean ARPA-H project (PAVE) for developing personalized cancer vaccines using NGS, mRNA, and LNP technologies. International collaborative research initiative for next-generation therapeutic development.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Foundation Medicine: Foundation Medicine is a leading molecular profiling company offering comprehensive genomic profiling assays for oncology. Comparable as a clinical NGS + bioinformatics services peer, though much larger and wholly owned by Roche, giving it incumbent scale advantages Theragen Bio lacks.
• Tempus AI: Tempus AI is a large-scale AI-powered precision medicine company offering NGS, multimodal data, and bioinformatic analysis to oncologists and pharma. Comparable on the AI-bioinformatics platform thesis, though operating at much larger scale across a broader portfolio than Theragen Bio's focused offering.
• BGI Group: BGI Group operates one of the world's largest genomic sequencing and bioinformatics service operations across clinical, agricultural, and research applications. Comparable on the genomics-services-plus-platform thesis, though operating as a global incumbent at materially larger scale.

Direct peers

• Personalis: Personalis is a US-based cancer genomics company combining NGS with proprietary AI for tumor molecular profiling and neoantigen discovery (ImmunoID Next platform). Comparable to Theragen Bio on the AI-driven oncology genomics and neoantigen prediction value proposition.
• Guardant Health: Guardant Health provides liquid-biopsy NGS-based oncology testing and biopharma services, including AI-driven interpretation. Comparable as a clinical NGS services + AI-bioinformatics company targeting precision oncology — a core customer segment for Theragen Bio.
• Caris Life Sciences: Caris offers molecular profiling plus ADAPT AI-based platform for biomarker discovery and therapy matching in oncology. Directly comparable to Theragen Bio's DEEPOMICS MARKER/Molecular-subtype-discovery approach combined with clinical sequencing services.
• Macrogen: Macrogen is a Korean-headquartered genomic services and precision medicine company offering NGS, bioinformatics, and clinical sequencing to pharma and academic clients. It is the most direct domestic competitor to Theragen Bio, with a comparable services-plus-bioinformatics model and similar Korean academic/hospital customer base.
• DNA Link: DNA Link is a Korean NGS services and bioinformatics provider serving clinical, academic, and pharma customers with DNA sequencing and AI-based analysis. It overlaps Theragen Bio on services portfolio, target segments (hospitals and research institutions), and Korean-market positioning.

Regional players

• Takara Bio: Takara Bio is a Japanese life-sciences company offering reagents, NGS services, and cell/gene therapy tools across Asia. Comparable as a regional player offering NGS-adjacent services and instruments to pharma/academic customers in the same geographies where Theragen Bio is expanding.
• Novogene: Novogene is a leading Asia-Pacific NGS services provider with strong footprint in China and global pharma clients. Comparable as a regional NGS services competitor, particularly relevant as Theragen Bio expands into Japan and broader East Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCxFMr_Xskhg0wTAWTiIvjhQ
• Facebookko-kr.facebook.com/theragenbio
• LinkedInlinkedin.com/company/theragen-bio

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theragen Bio